Zhang Pengcheng, Li Juan, Miao Yifan, Zhao Xianlin, Zhu Lv, Yao Jiaqi, Wan Meihua, Tang Wenfu
Regenerative Medicine Research Center, Sichuan University West China Hospital, Chengdu, China.
Department of Integrated Traditional Chinese and Western Medicine, West China Hospital, Sichuan University, Chengdu, China.
Front Microbiol. 2024 May 27;15:1387401. doi: 10.3389/fmicb.2024.1387401. eCollection 2024.
Intestinal microbiota have been demonstrated to be involved in the development of NAFLD, while the relationship between the severity of NAFLD and intestinal microbiota is still not fully elucidated. Sheng-Jiang Powder (SJP) showed exact efficacy in treating SFL and great potential in regulating intestinal microbiota, but the effects need to be further addressed in NASH and liver fibrosis.
To investigate the differences in intestinal microbiota of NAFLD with different severity and the effect of SJP on liver damage and intestinal microbiota.
NAFLD mice models with different severity were induced by high-fat diet (HFD) or choline-deficient, L-amino acid-defined high-fat diet (CDAHFD) feeding and then treated with SJP/normal saline.
Biochemical blood tests, H&E/Masson/Oil Red O/IHC staining, Western blot, and 16SrDNA sequencing were performed to explore intestinal microbiota alteration in different NAFLD models and the effect of SJP on liver damage and intestinal microbiota.
Intestinal microbiota alteration was detected in all NAFLD mice. SJP induced increased expression of Pparγ and alleviated liver lipid deposition in all NAFLD mice. Microbiome analysis revealed obvious changes in intestinal microbiota composition, while SJP significantly elevated the relative abundance of and , which were demonstrated to be beneficial for improving inflammation and intestinal barrier function.
Our results demonstrated that SJP was effective in improving lipid metabolism in NAFLD mice, especially in mice with SFL. The potential mechanism may be associated with the regulation of intestinal microbiota.
肠道微生物群已被证明与非酒精性脂肪性肝病（NAFLD）的发生发展有关，而NAFLD严重程度与肠道微生物群之间的关系仍未完全阐明。升降散（SJP）在治疗单纯性脂肪肝（SFL）方面显示出确切疗效，在调节肠道微生物群方面具有巨大潜力，但在非酒精性脂肪性肝炎（NASH）和肝纤维化方面的作用尚需进一步研究。
探讨不同严重程度的NAFLD患者肠道微生物群的差异以及SJP对肝损伤和肠道微生物群的影响。
通过高脂饮食（HFD）或胆碱缺乏、L-氨基酸限定的高脂饮食（CDAHFD）诱导不同严重程度的NAFLD小鼠模型，然后用SJP/生理盐水进行治疗。
进行生化血液检测、苏木精-伊红/马松/油红O/免疫组化染色、蛋白质免疫印迹法和16SrDNA测序，以探讨不同NAFLD模型中肠道微生物群的变化以及SJP对肝损伤和肠道微生物群的影响。
在所有NAFLD小鼠中均检测到肠道微生物群的改变。SJP诱导所有NAFLD小鼠中过氧化物酶体增殖物激活受体γ（Pparγ）表达增加，并减轻肝脏脂质沉积。微生物组分析显示肠道微生物群组成有明显变化，而SJP显著提高了[具体微生物名称未给出]的相对丰度，已证明这些微生物有利于改善炎症和肠道屏障功能。
我们的结果表明，SJP可有效改善NAFLD小鼠的脂质代谢，尤其是在SFL小鼠中。潜在机制可能与肠道微生物群的调节有关。
